MALT1 inhibitors and uses thereof

1. A compound of Formula (I):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R 3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R 4 is hydrogen, halogen, or optionally substituted alkyl;

R N is hydrogen, optionally substituted alkyl, optionally substituted acyl, or a nitrogen protecting group;

or R N and either R 3 or R 4 are joined to form an optionally substituted heterocyclic ring, or R 3 and R 4 are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

R 5 is hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R 6 is hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

or R 5 and R 6 are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

R 8 is optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, —C(═O)R 8b , —C(═O)N(R 8a ) 2 , —S(═O) 2 R 8a , or of formula

wherein each instance of R A is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, cyano, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted acyl;

each occurrence of R 8a and R 8b is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group when attached to an oxygen atom, or a nitrogen protecting group when attached to a nitrogen atom, or two R 8a are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring;

L 1 is a bond, an amino acid, or a dipeptide;

each of R c and R d is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a nitrogen protecting group;

R A1 is hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted sulfonyl, or a nitrogen protecting group; and

each of R A2 , R A3 , and R A4 is independently hydrogen, unsubstituted methyl, methyl substituted with one or more halogen, optionally substituted C 2-10 alkyl, —C(═O)R f , —C(═O)NH(R f ), —C(═O)N(R f ) 2 , optionally substituted sulfonyl, or a nitrogen protecting group selected from the group consisting of formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N′-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2′- and 4′-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, p-methoxybenzyl carbamate (Moz), p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p′-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, 2,4,6-trimethylbenzyl carbamate, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4′,8′-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, phenacylsulfonamide, phenothiazinyl-(10)-acyl derivative, N′-p-toluenesulfonylaminoacyl derivative, N′-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N′-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N—(N′,N′-dimethylaminomethylene)amine, N,N′-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys), wherein each occurrence of R f is independently hydrogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or a nitrogen protecting group when attached to a nitrogen atom, or two R f are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring;

or any two of R A1 , R A2 , R A3 , and R A4 are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring;

provided the compound is not of formula:

2. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 5 is hydrogen, halogen, or optionally substituted alkyl.

3. The compound of claim 1 ,

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R 5 is hydrogen, halogen, or optionally substituted alkyl;

each occurrence of R 8a and R 8b is independently hydrogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group when attached to an oxygen atom, or a nitrogen protecting group when attached to a nitrogen atom, or two R 8a are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring.

4. The compound of claim 1 , wherein the compound is of Formula (I-A), (I-B), or (I-D):

or a pharmaceutically acceptable salt or tautomer thereof.

5. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 3 and R N are joined to form an optionally substituted 4-6-membered heterocyclic ring.

6. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 3 is of formula:

7. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 4 and R N are joined to form an optionally substituted 5-membered heterocyclic ring.

8. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 4 is hydrogen.

9. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 5 and R 6 are each unsubstituted C 1-12 alkyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 5 and R 6 are joined to form an optionally substituted 3-6-membered carbocyclic or optionally substituted 3-6-membered heterocyclic ring.

11. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 6 is optionally substituted 5-6-membered carbocyclyl or optionally substituted 5-6-membered heterocyclyl.

12. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 6 is unsubstituted C 1-12 alkyl.

13. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 6 is of formula:

14. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 8 is —C(═O)R 8b , —C(═O)N(R 8a ) 2 , or of formula

15. The compound of claim 1 , wherein the compound is of formula:

or a pharmaceutically acceptable salt or tautomer thereof.

16. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein L 1 is a bond.

17. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 5 is hydrogen.

18. The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R 3 and R N are joined to form an optionally substituted pyrrolidine ring.

19. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt or tautomer thereof.

20. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt or tautomer thereof.

21. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable excipient.

22. A method of treating a proliferative disease comprising administering an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, to a subject in need thereof, wherein the proliferative disease is a cancer or autoimmune disease.

23. The method of claim 22 , wherein the proliferative disease is a cancer.

24. The method of claim 23 , wherein the cancer is lymphoma.

25. The method of claim 23 , wherein the cancer is diffuse large B-cell lymphoma.

26. The method of claim 23 , wherein the cancer is mantle cell lymphoma, primary effusion lymphoma, or MALT lymphoma.

27. The method of claim 23 , wherein the cancer is leukemia.

28. The method of claim 23 , wherein the cancer is chronic lymphocytic leukemia.

29. The method of claim 23 , wherein the cancer is lung cancer.

30. The method of claim 22 , wherein the proliferative disease is an autoimmune disease.

31. The method of claim 30 , wherein the autoimmune disease is multiple sclerosis.

32. A method of inhibiting MALT1 or API2-MALT1 in a subject, the method comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein the subject is in need of treatment of a cancer or autoimmune disease.

33. A method of inhibiting cleavage of A20, RelB, Bcl10, CYLD, regnase-1, roquin-1, roquin-2, NIK, LIMA1α, or MALT1 in a subject, the method comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein the subject is in need of treatment of a cancer or autoimmune disease.

34. A method of preparing a compound of claim 1 ,

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, the method comprising coupling a carboxylic acid of Formula (D):

or a salt thereof, and a compound of Formula (E):

or a salt thereof.